Intravenous thrombolysis for acute ischaemic stroke: Extension of the time window should not delay initiation of treatment;Behandeling van het acute herseninfarct met intraveneuze trombolyse: Meer tijd, maar geen minuut te verliezen

Nederlands Tijdschrift voor Geneeskunde

Volumn 152, Issue 49, 2008, Pages 2653-2655

  Uyttenboogaart, M ^a   Luijckx, G J ^a   Kappelle, L J ^b   Van Oostenbrugge, R J ^c   Dippel, D W J ^d   Stam, J ^e  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; PLACEBO;

BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; EARLY INTERVENTION; HUMAN; NOTE; RISK FACTOR; TIME;

FIBRINOLYTIC AGENTS; HUMANS; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 57649213799     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (13)

1. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-29.
2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-7.
3. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:1245-51.
4. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-25.
5. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study. A randomized controlled trial. JAMA. 1999;282:2019-26.
6. Wardlaw JM, del Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischaemic stroke [Cochrane review]. Cochrane Database Syst Rev. 2003;(2):CD000213.
7. Stam J, Koudstaal PJ, Franke CL, Kappelle LJ, Boiten J. Trombolyse voor het herseninfarct: het einde van het begin. Ned Tijdschr Geneeskd. 2000;144:1028-32.
8. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-74.
9. Uyttenboogaart M, Vroomen PC, Stewart RE, de Keyser J, Luijckx GJ. Safety of routine IV thrombolysis between 3 and 4.5 h after ischemic stroke. J Neurol Sci. 2007;254:28-32.
10. Wahlgren N, Ahmed N, Davalos A, Hacke W, Millan M, Muir K, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008;372:1303-9.
11. Lyden P. Thrombolytic therapy for acute stroke - not a moment to lose. N Engl J Med. 2008;359:1393-5.
12. Ingall TJ, O'Fallon WM, Asplund K, Goldfrank LR, Hertzberg VS, Louis TA, et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke. 2004;35:2418-24.
13. Engelter ST, Bonati LH, Lyrer PA. Intravenous thrombolysis in stroke patients of > or = 80 versus < 80 years of age - a systematic review across cohort studies. Age Ageing. 2006;35:572-80.